Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
Tice, C.M., Xu, Z., Yuan, J., Simpson, R.D., Cacatian, S.T., Flaherty, P.T., Zhao, W., Guo, J., Ishchenko, A., Singh, S.B., Wu, Z., Scott, B.B., Bukhtiyarov, Y., Berbaum, J., Mason, J., Panemangalore, R., Cappiello, M.G., Muller, D., Harrison, R.K., McGeehan, G.M., Dillard, L.W., Baldwin, J.J., Claremon, D.A.(2009) Bioorg Med Chem Lett 19: 3541-3545
- PubMed: 19457666 
- DOI: https://doi.org/10.1016/j.bmcl.2009.04.140
- Primary Citation of Related Structures:  
3GW5 - PubMed Abstract: 
Structure-based drug design led to the identification of a novel class of potent, low MW alkylamine renin inhibitors. Oral administration of lead compound 21l, with MW of 508 and IC(50) of 0.47nM, caused a sustained reduction in mean arterial blood pressure in a double transgenic rat model of hypertension.
Organizational Affiliation: 
Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, USA. ctice@vitaerx.com